Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 1997 Sep;18(9):338-44.

Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.

Author information

Pharmaceutical Development Centre, Kyowa Hakko Kogyo, Tokyo, Japan.


There is now good reason to believe that blockade of the adenosine A2A receptor could be of value in the treatment of Parkinson's disease. Peter J. Richardson, Hiroshi Kase and Peter G. Jenner review the actions of this receptor in the striatum, emphasizing its ability to modulate the neuronal activity of striatal GABA-releasing output neurones, and showing that recently developed A2A receptor antagonists are capable of reducing the disabling effects of nigral cell degeneration in primates. They conclude that such antagonists may be useful as novel therapeutic agents for the treatment of Parkinson's disease.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center